Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.24)
# 439
Out of 5,090 analysts
146
Total ratings
52.27%
Success rate
14.84%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Overweight | $200 → $150 | $16.51 | +808.54% | 7 | Dec 2, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $8.78 | +184.74% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $100.49 | +99.02% | 1 | Nov 6, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $85 → $95 | $68.48 | +38.73% | 6 | Nov 5, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.55 | +1,076.47% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $73.64 | +49.38% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $109.60 | +23.18% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $2.23 | +348.43% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $71.63 | -9.26% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $43.30 | +73.21% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.96 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $26.76 | -6.58% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $3.32 | +140.96% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.47 | +85.60% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $5.82 | +3.09% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $205.44 | +36.29% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.56 | +268.73% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $3.36 | +495.24% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $234.13 | -8.17% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.26 | +121.24% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.74 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $9.93 | +202.11% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.70 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.22 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $46.67 | +92.84% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.71 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $204.00 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.44 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.13 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.61 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $69.56 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.66 | +2,166.55% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $45.01 | +44.41% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $8.72 | -42.66% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $3.27 | +236.39% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $155.51 | -16.40% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $718.36 | +5.80% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $26.69 | -43.80% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $10.59 | +419.36% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.99 | +1,407.54% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.14 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.16 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $577.30 | -56.69% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $102.52 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $81.68 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.28 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $21.33 | +3.14% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.55 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $53.40 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $226.08 | -57.98% | 1 | Aug 17, 2017 |
Janux Therapeutics
Dec 2, 2025
Maintains: Overweight
Price Target: $200 → $150
Current: $16.51
Upside: +808.54%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $8.78
Upside: +184.74%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $100.49
Upside: +99.02%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $85 → $95
Current: $68.48
Upside: +38.73%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.55
Upside: +1,076.47%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $73.64
Upside: +49.38%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $109.60
Upside: +23.18%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.23
Upside: +348.43%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $71.63
Upside: -9.26%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $43.30
Upside: +73.21%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $19.96
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $26.76
Upside: -6.58%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.32
Upside: +140.96%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $13.47
Upside: +85.60%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $5.82
Upside: +3.09%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $205.44
Upside: +36.29%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $13.56
Upside: +268.73%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $3.36
Upside: +495.24%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $234.13
Upside: -8.17%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.26
Upside: +121.24%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.74
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $9.93
Upside: +202.11%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.70
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.22
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $46.67
Upside: +92.84%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.71
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $204.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.44
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.13
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $69.56
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.66
Upside: +2,166.55%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $45.01
Upside: +44.41%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $8.72
Upside: -42.66%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $3.27
Upside: +236.39%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $155.51
Upside: -16.40%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $718.36
Upside: +5.80%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $26.69
Upside: -43.80%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $10.59
Upside: +419.36%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.99
Upside: +1,407.54%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.14
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $13.16
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $577.30
Upside: -56.69%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $102.52
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $81.68
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.28
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $21.33
Upside: +3.14%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $18.55
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $53.40
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $226.08
Upside: -57.98%